Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas Pharma
Pharma
Astellas' Izervay wins key FDA label update after prior rejection
The geographic atrophy drug can now be dosed beyond a 12-month window, a prior label restriction that led many patients to pause treatment.
Zoey Becker
Feb 13, 2025 12:00pm
Astellas, Endo issue separate US drug recalls
Jan 3, 2025 9:20am
Astellas is closing down a gene therapy plant in California
Sep 4, 2024 12:46pm
Astellas, Yaskawa to explore automated cell therapy production
May 21, 2024 9:05am
'March-in' drug pricing provisions advance in the US
Dec 7, 2023 11:58am
Padcev, Keytruda combo posts 'practice-changing' win
Sep 22, 2023 11:28am